Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
z5Uw8Ah1214xxxkz